

# Routine immunization profile Cyprus

## Progress towards achieving European Vaccine Action Plan goals, 2017

Goal	Indicator	Status	Goal	Indicator	Status
<b>1</b>	Sustain polio-free status <sup>a</sup> (Current risk)	Yes (Low)	<b>4</b>	Meets vaccination coverage targets DTP3 national immunization coverage $\geq 95\%$ <sup>d</sup> $\geq 90\%$ DTP3 coverage achieved in $\geq 90\%$ of districts <sup>e</sup>	Yes Yes Yes
<b>2</b>	Measles elimination status <sup>b</sup>	Eliminated	<b>5</b>	Make evidence-based decisions about introduction of new vaccines* <sup>e</sup> NITAG made a recommendation about PCV NITAG made a recommendation about RV NITAG made a recommendation about HPV	No
	Rubella elimination status <sup>b</sup>	Eliminated			NN NN NN
<b>3</b>	Control hepatitis B infection <sup>c</sup>	Validation pending	<b>6</b>	Achieve financial sustainability of the national immunization programme** <sup>c</sup>	Yes

\*New vaccines introduced or not introduced based on NITAG evidence-based recommendations

\*\*Country self-sufficient for procuring routine vaccines

## Demographic, income and health expenditure summary, 2017

Total Population <sup>f</sup>	1 179 551
Live births	12 600
Surviving infants	12 554
<5 years	65 374
<15 years	198 519
Neonatal mortality rate (per 1000 live births) <sup>f</sup>	1.6
Infant mortality rate (per 1000 live births) <sup>f</sup>	2.1
Number of districts <sup>e</sup>	5
GNI (per capita, in USD) <sup>g</sup>	24 070
Health spending as % of total government expenditure <sup>g</sup>	7


## Immunization schedule, 2017<sup>e</sup>

2M	DTaPIPv, HepB_Pediatric, Hib, PCV
4M	DTaPIPv, HepB_Pediatric, Hib, PCV
6M	DTaPIPv, Hib
8-12M	HepB_Pediatric
12-13M	MenC_conj
12-15M	MMR, PCV
12-18M	Hib
15-18M	DTaPIPv
4-6Y	DTaPIPv, MMR
12-13Y	HPV (2x)
14-16Y	Td




### Vaccine coverage estimates, 2013-2017<sup>d</sup>


	2013	2014	2015	2016	2017
BCG	NR	NR	NR	NR	NR
HepB-BD	NR	NR	NR	NR	NR
DTP1	99	99	98	98	98
DTP3	99	99	97	97	97
HepB3	96	96	97	97	97
Hib3	96	96	97	96	96
Pol3	99	99	97	97	97
PCV3	ND	ND	81	81	81
Rotac	NR	NR	NR	NR	NR
RCV1	86	86	90	90	90
MCV1	86	86	90	90	90
MCV2	88	88	88	88	88




### DTP3 reported coverage by subnational area<sup>†</sup>, 2017<sup>e</sup>



### MCV1 reported coverage by subnational area<sup>†</sup>, 2017<sup>e</sup>



### MCV2 reported coverage by subnational area<sup>†</sup>, 2017<sup>e</sup>



### Number of reported cases of vaccine-preventable diseases, 2013-2017<sup>e</sup>


	2013	2014	2015	2016	2017
Measles	0	10	0	0	3
Mumps	0	1	2	1	2
Rubella	0	0	0	0	0
Congenital rubella syndrome	0	0	0	0	0
Diphtheria	0	0	0	0	0
Tetanus	0	0	0	0	0
Pertussis	9	7	2	2	17
Hepatitis A	2	8	4	3	6
Varicella	87	33	57	46	71

### Surveillance with laboratory confirmation of cases, 2017<sup>e</sup>


Measles	Yes
Rubella	Yes
Congenital rubella syndrome	Yes
Rotavirus	No
Invasive meningococcal disease	Yes
Invasive pneumococcal disease	Yes
Invasive <i>Haemophilus influenzae</i> disease	Yes

Note: Case-based surveillance (with laboratory confirmation of cases) assessed for measles, rubella, and congenital rubella syndrome. Hospital-based sentinel surveillance and/or population-based surveillance (both with laboratory confirmation of cases) assessed for rotavirus, invasive meningococcal disease, invasive pneumococcal disease, and invasive *Haemophilus influenzae* disease.


### Number of reported measles, mumps and rubella cases<sup>e</sup> and MCV coverage estimates<sup>d</sup>, 2013-2017




### Number of reported diphtheria, tetanus and pertussis cases<sup>e</sup> and DTP3 coverage estimates<sup>d</sup>, 2013-2017




### Reported target population, reported number of DTP3 doses administered and DTP3 reported coverage<sup>e</sup>, 2013-2017



### Percentage of districts by DTP3 reported coverage<sup>e</sup>, 2013-2017



### DTP1-DTP3 dropout rate, 2013-2017<sup>d</sup>



Note: Dropout rate is calculated using WUENIC

### Immunization system characteristics, 2017

Sustained access to WHO accredited polio, measles, and rubella laboratories <sup>h</sup>	Yes
NITAG in place that meets six WHO criteria <sup>e</sup>	No
National system in place to monitor AEFIs <sup>e</sup>	Yes
Communication plan in place to respond to vaccine safety-related events <sup>e</sup>	Yes
Vaccine hesitancy assessment performed within last 5 years <sup>e</sup>	Yes
Mandatory proof of immunization at school entry <sup>e</sup>	Yes

Note: The six WHO NITAG criteria are 1. legislative or administrative basis for the advisory group; 2. formal written terms of reference; 3. at least five different areas of expertise represented among core members; 4. at least one meeting per year; 5. circulation of the agenda and background documents at least one week prior to meetings; 6. mandatory disclosure of any conflict of interest

## Vaccine stockouts by administrative level<sup>a</sup>, 2013-2017

	2013	2014	2015	2016	2017
BCG	ND	No	ND	Both	No
DTP	ND	No	No	No	No
HepB	ND	No	No	No	Both
Hib	ND	No	No	No	No
Pneumo	ND	No	No	No	Both
Rota	NR	NR	NR	NR	NR
OPV	NR	NR	NR	NR	NR
IPV	ND	No	ND	No	No
Measles	ND	No	No	No	No
HPV	*	*	*	No	No
TT	ND	No	No	National	No

<span style="color: blue;">■</span>	No stockout
<span style="color: lightblue;">■</span>	Subnational level stockout only
<span style="color: orange;">■</span>	National level stockout only
<span style="color: red;">■</span>	Stockout at both levels
<span style="color: grey;">■</span>	NR
<span style="color: lightgrey;">■</span>	ND

\*Data on HPV stockouts have only been collected in JRF since 2016

## Abbreviations

AEFI	Adverse event following immunization	MCV1	measles-mumps-rubella vaccine, first dose
BCG	Bacille Calmette-Guerin vaccine for tuberculosis	MCV2	measles-mumps-rubella vaccine, second dose
CRS	congenital Rubella Syndrome	MMR	measles-mumps-rubella vaccine
DT	diphtheria-tetanus-containing vaccine	ND	Data not available
DTP	diphtheria-tetanus-pertussis-containing vaccine	NITAG	National Immunization Technical Advisory Group
DTP1	diphtheria-tetanus-pertussis-containing vaccine, first dose	NN	No NITAG
DTP3	diphtheria-tetanus-pertussis-containing vaccine, third dose	NR	Not relevant as vaccine not included in immunization schedule
GNI	Gross national income	OPV	oral polio vaccine
HepB	hepatitis B	PCV	pneumococcal conjugate vaccine
HepB3	hepatitis B vaccine, third dose	PCV3	pneumococcal conjugate vaccine , third dose
HepB-BD	hepatitis B vaccine, birth dose	Pol3	polio-containing vaccine, third dose
Hib	Haemophilus influenzae type b	RCV1	rubella-containing vaccine, first dose
Hib3	Haemophilus influenzae type b vaccine, third dose	Rotac	rotavirus vaccine-complete series
HPV	human papillomavirus	Td	tetanus-diphtheria-containing vaccine
IPV	inactivated polio vaccine	TT	tetanus toxoid vaccine
MCV	measles-containing vaccine	W,M,Y	Weeks, Months, Years

## Data sources

- a European Regional Commission for Certification of Poliomyelitis eradication (RCC) meeting report: [www.euro.who.int/32ndRCC](http://www.euro.who.int/32ndRCC)
- b European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: [www.euro.who.int/7thRVC](http://www.euro.who.int/7thRVC)
- c European Vaccine Action Plan 2015-2020 Midterm report
- d WHO/UNICEF Estimates of National Immunization Coverage (WUENIC): ([http://www.who.int/immunization/monitoring\\_surveillance/data/en/](http://www.who.int/immunization/monitoring_surveillance/data/en/))
- e WHO/UNICEF Joint Reporting Form on immunization (JRF)
- f World Population Prospects: The 2017 Revision, New York, United Nations
- g World Bank, World Development Indicators
- h Polio Laboratory Network: [www.euro.who.int/poliolabnetwork](http://www.euro.who.int/poliolabnetwork) & Personal communication based on annual accreditation process of the European Measles and Rubella Laboratory Network

## Map disclaimer

† The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.